

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (10 ml,  
5 x 10 ml, 6 x 10 ml)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Mepidor 20 mg/ml solution for injection

Mepivacaine hydrochloride

**2. STATEMENT OF ACTIVE SUBSTANCES**

Mepivacaine hydrochloride 20 mg/ml

**3. PACKAGE SIZE**

10 ml

5 x 10 ml

6 x 10 ml

**4. TARGET SPECIES**

Horses (non-food producing horses)

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

For infiltration, for perineural, intra-articular and epidural use.

**7. WITHDRAWAL PERIODS**

Not authorised for use in horses producing meat or milk for human consumption.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

The veterinary medicinal product should not be administered by pregnant women.  
Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VetViva Richter (logo)

**14. MARKETING AUTHORISATION NUMBERS**

Vm 57446/4006

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 10 ml clear glass vial type I with bromobutyl rubber stopper and alu-caps**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Mepidor



Horses (non-food producing)

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Mepivacaine hydrochloride 20 mg/ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

10 ml

VetViva Richter (logo)

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Mepidor 20 mg/ml solution for injection

#### **2. Composition**

Each ml contains:

##### **Active substances:**

Mepivacaine hydrochloride 20 mg  
(equivalent to 17.4 mg mepivacaine)

Clear, colourless to slightly yellow solution

#### **3. Target species**

Horses (non-food producing horses)

#### **4. Indications for use**

Mepivacaine is indicated for infiltration, nerve block, intra-articular and epidural anaesthesia in non-food producing horses.

#### **5. Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

#### **6. Special warnings**

##### Special precautions for safe use in the target species:

Aspirate prior to and during administration to avoid intra-vascular injection.

The analgesic effect of mepivacaine, when used as part of a lameness investigation, begins to subside after 45 - 60 minutes. However, sufficient analgesia may persist to effect gait beyond two hours.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- People with known hypersensitivity to mepivacaine or other local anaesthetics of the amide group should avoid contact with the veterinary medicinal product.
- This veterinary medicinal product may be irritant to the skin and eyes.
- Avoid contact with the skin and eyes. Wash any splashes from skin and eyes immediately with plenty of water. Seek medical advice if irritation persists.

- Adverse effects on the foetus cannot be excluded. The veterinary medicinal product should not be administered by pregnant women.
- Accidental self-injection may result in cardiorespiratory and/or CNS effects. Care should be taken to avoid accidental self-injection. In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive.
- Wash hands after use.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Mepivacaine crosses the placenta. There is no evidence that mepivacaine is associated with reproductive toxicity or teratogenic effects. However, there is a potential for anaesthetics of the amide group such as mepivacaine to accumulate in the equine foetus resulting in neonatal depression and interfering with resuscitation efforts. Therefore, use in obstetric anaesthesia only according to the benefit/risk assessment of the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

None known.

Overdose:

Symptoms related to overdose correlate with symptoms occurring after inadvertent intravascular injection as described in section "Adverse reactions".

<Special restrictions for use and special conditions for use:>

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with any other veterinary medicinal products.

## **7. Adverse events**

### **Horses:**

Undetermined frequency (cannot be estimated from the available data):  
Injection site swelling<sup>1</sup>, Central nervous system disorder<sup>2</sup>, Convulsion<sup>3</sup>, Cardiac depression<sup>2,4</sup>, Respiratory depression<sup>2,4</sup>.

<sup>1</sup> Transient, local soft tissue swelling may occur in a small proportion of cases following injection of the veterinary medicinal product.

<sup>2</sup> In case of inadvertent intra-vascular injection or excessive use local anaesthetics can cause systemic toxicity.

<sup>3</sup> Administration of diazepam should be considered.

<sup>4</sup> Administration of oxygen should be considered.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing

authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **8. Dosage for each species, routes and method of administration**

Full aseptic precautions should be observed when injecting the veterinary medicinal product.

For infiltration: As required but as a guide 2 - 5 ml.

For nerve block: 2 - 10 ml depending on location.

For intra-articular anaesthesia: 5 ml.

For epidural anaesthesia: 4 - 10 ml depending on the depth and extent of anaesthesia required.

In all instances the dosage should be kept to the minimum required to produce the desired effect. The depth and extent of anaesthesia should be determined by pressure with a blunt point, such as the tip of a ball point pen, before commencing manipulations. The duration of action is about 1 hour. It is recommended that the skin should be shaved and thoroughly disinfected prior to the intra-articular or epidural administration.

This veterinary medicinal product does not contain an antimicrobial preservative. Use the vial on one occasion only. Discard any unused material.

## **9. Advice on correct administration**

See section "Special warnings".

## **10. Withdrawal periods**

Not to be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation. Not authorised for use in horses producing milk for human consumption.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Keep the vial in the outer carton in order to protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after “Exp.”. The expiry date refers to the last day of that month. Shelf life after first opening the immediate packaging: Use immediately.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

## **14. MARKETING AUTHORISATION NUMBER AND PACK SIZES**

Vm 57446/4006

Pack sizes: 10 ml, 5 x 10 ml, 6 x 10 ml.

Not all pack sizes may be marketed.

## **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the ‘Product Information Database’ on [www.gov.uk](http://www.gov.uk).

## **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse events:

VetViva Richter GmbH, Durisolstrasse 14, 4600 Wels, Austria

Tel: +43 (0)664 8455326

E-mail: [adverse.events@vetviva.com](mailto:adverse.events@vetviva.com)

## **17. Other information**

POM-V

*Gavin Hall*  
Approved: 13 February 2026